Stockscreener 앱 받기
39.87
0.30%
0.12
전일 마감가:
$39.75
열려 있는:
$39.69
하루 거래량:
2.94M
Relative Volume:
1.16
시가총액:
$6.17B
수익:
$15.06M
순이익/손실:
$-250.69M
주가수익비율:
-22.46
EPS:
-1.7748
순현금흐름:
$-209.28M
1주 성능:
+0.45%
1개월 성능:
+0.71%
6개월 성능:
+59.61%
1년 성능:
+216.43%
1일 변동 폭
$39.69
$39.90
1주일 범위
$39.64
$39.90
52주 변동 폭
$12.30
$40.26
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
명칭
Centessa Pharmaceuticals Plc Adr
전화
44 7391 789784
주소
3RD FLOOR, ALTRINCHAM, CHESHIRE
Compare CNTA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNTA
Centessa Pharmaceuticals Plc Adr
|
39.87 | 6.15B | 15.06M | -250.69M | -209.28M | -1.7748 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 다운그레이드 | Truist | Buy → Hold |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2025-12-10 | 재개 | Oppenheimer | Outperform |
| 2025-10-28 | 개시 | Stephens | Overweight |
| 2025-09-03 | 개시 | Wells Fargo | Overweight |
| 2025-08-29 | 재개 | Oppenheimer | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-05-28 | 개시 | Needham | Buy |
| 2025-05-08 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-31 | 개시 | Piper Sandler | Overweight |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-09-20 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-19 | 개시 | B. Riley Securities | Buy |
| 2024-07-18 | 개시 | Oppenheimer | Outperform |
| 2023-11-15 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-10-26 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-06-21 | 개시 | Evercore ISI | Outperform |
| 2023-06-12 | 개시 | Guggenheim | Buy |
| 2023-03-17 | 개시 | SVB Securities | Outperform |
| 2022-08-12 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-06-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-02-11 | 개시 | Goldman | Neutral |
모두보기
Centessa Pharmaceuticals Plc Adr 주식(CNTA)의 최신 뉴스
Centessa (NASDAQ: CNTA) investors approve Eli Lilly acquisition scheme - Stock Titan
TD Asset Management Inc Decreases Stake in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Gold gains over 1%; FactSet Research raises FY2026 outlook - MSN
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—RAMP, NEE, CNTA, and HCBN - GlobeNewswire Inc.
Eli Lilly, Centessa Pharmaceuticals receive US green light - MLex
HSR waiting period lapses for Centessa (CNTA) sale to Eli Lilly under UK scheme - Stock Titan
LLY to buy neuroscience biotech Centessa Pharmaceuticals in $7.8B deal - MSN
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plcCNTA - ChartMill
Centessa (NASDAQ: CNTA) to be acquired by Lilly for $38 plus up to $9 CVR - Stock Titan
Is It Too Late To Consider Centessa Pharmaceuticals (CNTA) After A 191% One Year Surge? - Yahoo Finance
Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 12-Month HighStill a Buy? - MarketBeat
LLY Stock Jumps After Q1 Earnings Beat, 2026 Guidance Raised - TradingView
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Centessa (NASDAQ: CNTA) schedules 2026 AGM and advisory pay vote - Stock Titan
38,432 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Acquired by B. Metzler seel. Sohn & Co. AG - MarketBeat
Should You Buy, Sell or Hold Lilly Stock Before Q1 Earnings? - TradingView
Wells Fargo Downgrades Centessa Pharmaceuticals ADR to Equal Weight From Overweight, Adjusts Price Target to $42 From $35 - marketscreener.com
Lilly to buy Centessa (NASDAQ: CNTA) for $38/ share plus $9 CVR - Stock Titan
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? - Finviz
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? - Sahm
Free cash flow per share of Centessa Pharmaceuticals PLC ADR – MUN:260 - TradingView
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy - Sahm
This Akamai Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Sahm
Centessa Pharmaceuticals Plc Adr (CNTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Centessa Pharmaceuticals Plc Adr 주식 (CNTA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Anderson Karen M. | Chief People Officer |
Mar 26 '26 |
Sale |
30.12 |
41,076 |
1,237,382 |
62,085 |
| Weinhoff Gregory M | Chief Business Officer |
Mar 26 '26 |
Option Exercise |
3.85 |
23,998 |
92,392 |
89,923 |
| Weinhoff Gregory M | Chief Business Officer |
Mar 26 '26 |
Sale |
30.00 |
23,998 |
719,940 |
65,925 |
2.60%
0.94%
자본화:
|
볼륨(24시간):